Some breast cancers are thought to be hereditary, caused by abnormal genes passed from parent to child. Most cases of hereditary breast cancer are associated with inherited mutations in two genes: BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two). Together BRCA1 and BRCA2 mutations account for about 25 to 30 percent of hereditary breast cancers, and approximately three to six percent of all breast cancers.
While all patients with metastatic breast cancer (MBC) face a complex and difficult journey, those whose disease can be attributed to inherited gene mutations could face unique challenges. These can include, but are not limited to, lack of access to support services, or genetic counseling. Importantly, it also can include the weight of knowing that others in their family may be at risk.
Join us for a webinar with Dr. Lily Shahied Arruda, Medical Director, U.S. Medical Affairs at Pfizer Oncology, when we will learn more about breast cancer patients’ experiences and knowledge of hereditary breast cancer and genetic testing.
Advance Registration is required to attend this webinar. Click on the “Register Now” button below to save your spot.
After registering, you will receive a confirmation email containing information about joining the webinar.
[maxbutton id=”34″ url=”https://zoom.us/webinar/register/WN_MJw3ccEVS5yZ_oDBySBJ9Q” text=”REGISTER NOW!” ]